Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching between tucatinib + fulvestrant and trastuzumab deruxtecan in HR-positive/HER2-low metastatic breast cancer
ChiCTR2600128463Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tucatinib, fulvestrant and trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tucatinibfulvestranttrastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600128463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128463.